In Hiroshima, Tresiba (Insulin Degludec) Effect and Safty in Diabetes study

In Hiroshima, Tresiba (Insulin Degludec) Effect and Safty in Diabetes study - Hiroshima Trendy Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011037

Enrollment

120

Registered

2013-06-26

Start date

2013-05-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who is adapted for insulin therapy, and is suited for conditions below 1. Tresiba has never used 2. Who chan inject insulin themselves

Exclusion criteria

Exclusion criteria: 1. who use insulin only short term 2. women in pregnant or during lactation

Design outcomes

Primary

Measure	Time frame
achievment rate of HbA1c <6.9%	—

Secondary

Measure	Time frame
number of all adverse events, achievment rate of fasting blood glucose < 80-100 mg/dl, variation of HbA1c, variation of fasting blood glucose and blood glucose before dinner, variation of body weight, number of all low blood glucose phenomenon	—

Countries

Japan

Contacts

Public ContactKazuhiro Kobuke

Hiroshima University Hospital Department of Endocrinology and Metabolism

kazu-kobuke@hiroshima-u.ac.jp082-257-5198

Outcome results